MPLU Biorefining Aps

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  9.4% 9.7% 4.4% 5.4% 3.7%  
Credit score (0-100)  27 25 46 41 51  
Credit rating  BB BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  85 281 0 0 0  
Gross profit  81.1 281 -3.0 -25.0 80.8  
EBITDA  81.1 281 -3.0 -25.0 80.8  
EBIT  81.1 281 -3.0 -25.0 80.8  
Pre-tax profit (PTP)  78.7 278.1 -6.2 -26.5 67.8  
Net earnings  61.3 217.0 -6.2 -26.9 56.7  
Pre-tax profit without non-rec. items  78.7 278 -6.2 -26.5 67.8  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  71.3 227 293 281 338  
Interest-bearing liabilities  0.0 0.0 130 161 310  
Balance sheet total (assets)  214 288 423 452 684  

Net Debt  -90.5 -165 96.3 150 307  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  85 281 0 0 0  
Net sales growth  0.0% 230.3% -100.0% 0.0% 0.0%  
Gross profit  81.1 281 -3.0 -25.0 80.8  
Gross profit growth  0.0% 246.0% 0.0% -733.9% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  214 288 423 452 684  
Balance sheet change%  66.1% 35.0% 46.8% 6.9% 51.1%  
Added value  81.1 280.6 -3.0 -25.0 80.8  
Added value %  95.2% 99.7% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 1.0 -1.0 0.0 0.0  
EBIT trend  1.0 2.0 -1.0 -2.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  95.2% 99.7% 0.0% 0.0% 0.0%  
EBIT %  95.2% 99.7% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  72.0% 77.1% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  72.0% 77.1% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  92.3% 98.8% 0.0% 0.0% 0.0%  
ROA %  47.4% 111.9% -0.8% -5.7% 14.2%  
ROI %  209.4% 188.2% -0.9% -5.8% 14.8%  
ROE %  158.4% 145.5% -2.4% -9.4% 18.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  33.4% 78.8% 69.3% 62.2% 49.5%  
Relative indebtedness %  166.8% 21.7% 0.0% 0.0% 0.0%  
Relative net indebtedness %  60.6% -36.9% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -111.6% -58.8% -3,209.3% -599.8% 379.7%  
Gearing %  0.0% 0.0% 44.3% 57.2% 91.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 4.9% 1.0% 5.5%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.6 2.7 0.0 2.7 3.9  
Current Ratio  0.6 2.7 0.0 2.7 3.9  
Cash and cash equivalent  90.5 165.1 33.6 10.9 2.9  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  106.2% 58.7% 0.0% 0.0% 0.0%  
Net working capital  -51.7 104.0 38.0 16.9 104.5  
Net working capital %  -60.6% 36.9% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0